Rekindling the debate over using CRISPR to edit human embryos

crispr
Image credit: vchalup / Fotolia
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Facing criticism from fellow scientists, the researcher behind the world’s largest effort to edit human embryos with CRISPR is vowing to continue his efforts to develop what he calls “IVF gene therapy.”

Shoukhrat Mitalipov, of Oregon Health Sciences University in Portland, drew global headlines last August when he reported successfully repairing a genetic mutation in dozens of human embryos, which were later destroyed as part of the experiment.

The breakthrough drew wide attention, including from critics who quickly pounced, calling it biologically implausible and potentially the result of careless errors and artifacts.

Today, those critics are getting an unusual hearing in the journal Nature, which is publishing two critiques of the Oregon research as well as a lengthy reply from Mitalipov and 31 of his coworkers in South Korea, China, and the Salk Institute in La Jolla, California.

Related article:  Australia adopts relaxed CRISPR gene-editing rules, 'middle ground' between US, EU extremes

The scientific sparring centers on CRISPR’s well-known tendency to introduce unseen damage into a cell’s DNA.

Mitalipov remains intent on proving that CRISPR can work safely on embryos. …he believes it will take five to 10 years before the process is ready to attempt in an IVF center.

Mitalipov says trying out CRISPR on embryos is the only way to make progress…

“If we don’t do it, it will never come closer,” he says.

Read full, original post: US scientist who edited human embryos with CRISPR responds to critics

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend